Ligand Pharmaceuticals, Inc’s filing revealed that its Director KOZARICH JOHN W unloaded Company’s shares for reported $0.12 million on Jul 10 ’25. In the deal valued at $125.00 per share,934 shares were sold. As a result of this transaction, KOZARICH JOHN W now holds 46,456 shares worth roughly $6.15 million.
Then, KOZARICH JOHN W bought 934 shares, generating $116,750 in total proceeds.
Before that, Reardon Andrew sold 500 shares. Ligand Pharmaceuticals, Inc shares valued at $57,042 were divested by the CLO & Secretary at a price of $114.08 per share. As a result of the transaction, Reardon Andrew now holds 31,903 shares, worth roughly $4.23 million.
Stifel initiated its Ligand Pharmaceuticals, Inc [LGND] rating to a Buy in a research note published on April 10, 2025; the price target was $143. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early October with a ‘”an Outperform”‘ rating. RBC Capital Mkts began covering LGND with “an Outperform” recommendation on July 30, 2024.
Price Performance Review of LGND
On Tuesday, Ligand Pharmaceuticals, Inc [NASDAQ:LGND] saw its stock fall -6.14% to $132.46. Over the last five days, the stock has gained 6.56%. Ligand Pharmaceuticals, Inc shares have risen nearly 33.85% since the year began. Nevertheless, the stocks have risen 23.62% over the past one year. While a 52-week high of $143.13 was reached on 07/21/25, a 52-week low of $90.29 was recorded on 04/09/25.
Levels Of Support And Resistance For LGND Stock
The 24-hour chart illustrates a support level at 128.71, which if violated will result in even more drops to 124.95. On the upside, there is a resistance level at 139.26. A further resistance level may holdings at 146.05.
How much short interest is there in Ligand Pharmaceuticals, Inc?
A steep rise in short interest was recorded in Ligand Pharmaceuticals, Inc stocks on 2025-06-30, dropping by 40270.0 shares to a total of 1.19 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-30 was 1.23 million shares. There was a decline of -3.39%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 04, 2021 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $310.
